Detail akcie Assertio Hldgs Rg online

Business Summary: Assertio Holdings, Inc. is a pharmaceutical company offering differentiated products to patients. The Company has built its commercial portfolio through the acquisition or licensing of approved products. Its commercial capabilities include marketing through both a sales force and an omni-channel promotion model, market access through payor contracting, and trade and distribution. The Company’s primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, and CAMBIA (diclofenac potassium for oral solution). INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID). Otrexup is a once weekly single-dose auto-injector containing methotrexate.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Assertio Holdings Inc revenues increased 13% to $105.2M. Net loss increased 66% to $18.4M. Revenues reflect ROLVEDON segment increase from $30.2M to $67.8M, other segment increase from $620K to $9.5M, Sympazan segment increase of 55% to $8.3M, United States segment increase of 74% to $105.2M. Higher net loss reflects United States segment loss increase of 47% to $9.8M.